Gleevec (Imatinib, STI751), a drug originally developed to inhibit the Bcr-Abl fusion protein found in chronic myelogenous leukaemia, also shows substantial inhibitory activity against PDGFRs and KIT and is currently used in the first line therapy for GIST patients. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.